Clin Infect Dis. 1992 Nov;15:S228-35. doi: 10.1093/clind/15.supplement_1.s228.

Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

H L DuPont, M Cooperstock, M L Corrado, R Fekety, D M Murray

PMID: 1477234 DOI: 10.1093/clind/15.supplement_1.s228

Abstract

This guideline includes diarrhea causing infantile mortality in which a bacterial pathogen is recovered and for which oral rehydration therapy is an important component of care as well as traveler's diarrhea (with or without recovery of a pathogen). Diarrhea is defined as the passage of three or more unformed stools per day plus--in all patients except infants--one or more signs or symptoms of enteric infection. The preferred study design is prospective and randomized, with an active concurrent control and (when possible) blinding. Placebo-controlled trials may be performed if the severity of disease is judged by the investigator to be mild or moderate. It is desirable that both clinical and microbiological outcome be determined. Microbiological eradication is paramount.

Similar articles

Cited by

Substances

• Anti-Infective Agents

MeSH terms

• Acute Disease
• Anti-Infective Agents / therapeutic use
• Bacterial Infections / drug therapy
• Clinical Protocols / standards
• Clinical Trials as Topic / standards
• Clinical Trials, Phase I as Topic / standards
• Clinical Trials, Phase II as Topic / standards
• Clinical Trials, Phase III as Topic / standards
• Diarrhea / drug therapy
• Humans
• Research Design

Publication Types

• Guideline
• Journal Article
• Research Support, U.S. Gov't, P.H.S.

Grant support

• HHS-223-88-1301/HS/AHRQ HHS/United States

LinkOut - more resources

• Full Text Sources
  • Silverchair Information Systems
• Medical
  • Genetic Alliance
  • MedlinePlus Health Information